Topical therapies for osteoarthritis

Drugs

Volumn 71, Issue 10, 2011, Pages 1259-1279

  Altman, Roy D ^a   Barthel, H Richard ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Private Practice   (United States)

Author keywords

Aspirin; Capsaicin; Clopidogrel; Corticosteroids; Diclofenac; Drug interactions; Eltenac; Felbinac; Fenbufen; Ibuprofen; Ketoprofen; Naproxen; Nonsteroidal anti inflammatories; Osteoarthritis; Paracetamol; Piroxicam; Proton pump inhibitors; Salicylates; Serotonin uptake inhibitors; Topical; Warfarin.

Indexed keywords

CAPSAICIN; CELECOXIB; DICLOFENAC; DICLOFENAC DIETHYLAMINE; DIMETHYL SULFOXIDE; FELBINAC; IBUPROFEN; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; SALICYLIC ACID;

ANALGESIA; ANGINA PECTORIS; APPLICATION SITE BURNING; APPLICATION SITE DERMATITIS; BLISTER; CONTACT DERMATITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HALITOSIS; HAND OSTEOARTHRITIS; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; KNEE OSTEOARTHRITIS; LIVER TOXICITY; NAUSEA; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TASTE DISORDER; TASTE PERVERSION; VASODILATATION;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSAICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OSTEOARTHRITIS; PRACTICE GUIDELINES AS TOPIC; SALICYLATES; SENSORY SYSTEM AGENTS;

EID: 79960519468     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11592550-000000000-00000     Document Type: Review

References (108)

1. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont (IL): American Academy of Orthopaedic Surgeons, 2008.
2. National Collaborating Centre for Chronic Conditions. Osteoarthritis: the care and management of osteoarthritis in adults. London: Royal College of Physicians, 2008.
3. ZhangW,DohertyM, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). AnnRheumDis 2007; 66 (3): 377-88. (Pubitemid 46579641)
4. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137-62. (Pubitemid 351222155)
5. Schilling A, Corey R, Leonard M, et al. Acetaminophen: old drug, new warnings. Cleve Clin J Med 2010 Jan; 77 (1): 19-27.
6. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010 Apr; 18 (4): 476-99.
7. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested casecontrol analysis. BMJ 2005 Dec 3; 331 (7528): 1310-6.
8. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 Jul; 63 (7): 759-66. (Pubitemid 38850444)
9. Franceschi M, Di Mario F, Leandro G, et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 2009; 23 (6): 839-48.
10. Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007 Mar; 66 (3): 417-8. (Pubitemid 46579647)
11. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Jun 11; 330 (7504): 1366.
12. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007 Mar 27; 115 (12): 1634-42. (Pubitemid 46648649)
13. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29 (7): 621-32. (Pubitemid 44175032)
14. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005 Mar; 45 (3): 531-9. (Pubitemid 40341332)
15. WheltonA.Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999 May 31; 106 (5B): 13S-24S. (Pubitemid 29268660)
16. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and antiinflammatory drugs-NSAIDs. Am J Ther 2004 Mar-Apr; 11 (2): 124-9.
17. Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010 Aug; 69 (8): 1453-8.
18. Barkin RL, Beckerman M, Blum SL, et al. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010 Oct 1; 27 (10): 775-89.
19. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005 Apr 19; 45 (8): 1295-301. (Pubitemid 40523153)
20. Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008 Jan; 48 (1): 117-22. (Pubitemid 350292265)
21. Cheetham TC, Levy G, Niu F, et al. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009 Nov; 43 (11): 1765-73.
22. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 Mar 4; 301 (9): 937-44.
23. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar 31; 180 (7): 713-8.
24. American Geriatrics Society. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331-46.
25. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 2004 Aug 19; 5: 28.
26. Voltaren Gel 1% (diclofenac sodium topical gel): full prescribing information. Parsippany, (NJ): Novartis Consumer Health, Inc., 2009.
27. PENNSAID (diclofenac sodium topical solution): full prescribing information. Varennes (QC): Nuvo Manufacturing, 2010.
28. Mason L, Moore RA, Edwards JE, et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004 Apr 24; 328 (7446): 995.
29. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004 Apr 24; 328 (7446): 991.
30. Cordero JA, Camacho M, Obach R, et al. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm 2001 Mar; 51 (2): 135-42. (Pubitemid 32162492)
31. Rao P,Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008; 11 (2): 81s-110s.
32. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006 Mar; 99 (3): 132-40.
33. Harris RC. COX-2 and the kidney. J Cardiovasc Pharmacol 2006; 47 Suppl. 1: S37-42. (Pubitemid 44651783)
34. Brzozowski T, Konturek PC, Konturek SJ, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 2001 Jun 1; 53 (5): 343-53. (Pubitemid 32494584)
35. Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs 2010 Jan; 50: 50-61.
36. Sioufi A, Pommier F, Boschet F, et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Dispos 1994 Aug; 15 (6): 441-9. (Pubitemid 24255658)
37. Gallacchi G, Marcolongo R. Pharmacokinetics of diclofenac hydroxyethylpyrrolidine (DHEP) plasters in patients with monolateral knee joint effusion. Drugs Exp Clin Res 1993; 19 (3): 95-7. (Pubitemid 24000675)
38. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987 Jan; 69 (1): 180-6. (Pubitemid 17007095)
39. Barthel HR, Haselwood D, Longley 3rd S, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009 Dec; 39 (3): 203-12.
40. Radermacher J, Jentsch D, Scholl MA, et al. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 1991 May; 31 (5): 537-41.
41. Gondalf-Zink B, Gronwald U. Active substance concentration in articular and periarticular tissues of the knee joint after cutaneous application of diclofenacdiethylammonium Emulgel [in German]. Aktuelle Rheumatologie 1996; 21: 298-304. (Pubitemid 27057634)
42. Riess W, Schmid K, Botta L, et al. The percutaneous absorption of diclofenac [in German]. Arzneimittelforschung 1986 Jul; 36 (7): 1092-6.
43. Singh P, Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther 1994 Jan; 268 (1): 144-51. (Pubitemid 24039081)
44. Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Sep; 36 (9): 1991-9.
45. Zacher J, Burger KF, Farber L. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes): double-blind, controlled, randomized study [in German]. Aktuelle Rheumatologie 2001; 26: 7-14. (Pubitemid 32217433)
46. Widrig R, Suter A, Saller R, et al. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 2007 Apr; 27 (6): 585-91. (Pubitemid 46411900)
47. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992 Apr; 19 (4): 604-7.
48. Barthel HR, Peniston JH, Clark M, et al. Correlation of pain relief with physical function in hand osteoarthritis: a randomized controlled trial post hoc analysis. Arthritis Res Ther 2010; 12 (1): R7.
49. Bravo CJ, Rizzo M, Hormel KB, et al. Pyrolytic carbon proximal interphalangeal joint arthroplasty: results with minimum two-year follow-up evaluation. J Hand Surg Am 2007 Jan; 32 (1): 1-11. (Pubitemid 46048933)
50. Field J. Two to five year follow-up of the LPM ceramic coated proximal interphalangeal joint arthroplasty. J Hand Surg Eur Vol 2008 Feb; 33 (1): 38-44. (Pubitemid 351583077)
51. Johnstone BR, Fitzgerald M, Smith KR, et al. Cemented versus uncemented surface replacement arthroplasty of the proximal interphalangeal joint with a mean 5-year follow-up. J Hand Surg Am 2008 May-Jun; 33 (5): 726-32. (Pubitemid 351885262)
52. Takigawa S, Meletiou S, Sauerbier M, et al. Long-term assessment of Swanson implant arthroplasty in the proximal interphalangeal joint of the hand. J Hand Surg Am 2004 Sep; 29 (5): 785-95. (Pubitemid 39311573)
53. Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 2004 May; 86-A (5): 963-74. (Pubitemid 38619796)
54. Virolainen P, Aro HT. High tibial osteotomy for the treatment of osteoarthritis of the knee: a review of the literature and a meta-analysis of follow-up studies. Arch Orthop Trauma Surg 2004 May; 124 (4): 258-61. (Pubitemid 38878345)
55. Grace D, Rogers J, Skeith K, et al. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999 Dec; 26 (12): 2659-63.
56. Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005 Dec; 32 (12): 2384-92. (Pubitemid 41780652)
57. Baraf HS, Gold MS, Clark MB, et al. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed 2010 Jun; 38 (2): 19-28.
58. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Apr 18; 143 (3): 238-45.
59. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004 Oct; 31 (10): 2002-12. (Pubitemid 39336727)
60. Baraf HSB, Gloth FM, Barthel HR, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebocontrolled, multicentre trials. Drugs Aging 2011; 28 (1): 27-40.
61. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005 Jan; 64 (1): 29-33. (Pubitemid 40075270)
62. Berner T, Gold MS, Speiller M. Correlation of pain relief with function and global rating of disease in knee osteoarthritis: data from randomized controlled trials of diclofenac sodium 1% gel. Academy of Nurse Practitioners 24th National Conference; 2009 Jun 17-21; Austin (TX).
63. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005; 6: 44.
64. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004 Oct 11; 164 (18): 2017-23. (Pubitemid 39390559)
65. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. Pain Med 2009 Sep; 10 (6): 1062-83.
66. Ottillinger B, Gomor B, Michel BA, et al. Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001 Apr; 9 (3): 273-80. (Pubitemid 32390210)
67. Sandelin J, Harilainen A, Crone H, et al. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee: a double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol 1997; 26 (4): 287-92. (Pubitemid 27390759)
68. Hosie G, Bird H. The topical NSAID felbinac versus oral NSAIDS: a critical review. Eur J Rheumatol Inflamm 1994; 14 (4): 21-8.
69. Rovensky J, Micekova D, Gubzova Z, et al. Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug: results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001; 27 (5-6): 209-21. (Pubitemid 34242052)
70. Trnavsky K, Fischer M, Vogtle-Junkert U, et al. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis: results of a randomized, double-blind, placebocontrolled study. J Rheumatol 2004 Mar; 31 (3): 565-72. (Pubitemid 38337620)
71. Kozanoglu E, Basaran S, Guzel R, et al. Short term efficacy of ibuprofen phonophoresis versus continuous ultrasound therapy in knee osteoarthritis. Swiss Med Wkly 2003 Jun 14; 133 (23-24): 333-8. (Pubitemid 36957885)
72. Underwood M, Ashby D, Cross P, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. [comment]. BMJ 2008 Jan 19; 336 (7636): 138-42. (Pubitemid 351211965)
73. RotherM, Lavins BJ, Kneer W, et al. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007 Sep; 66 (9): 1178-83. (Pubitemid 47309734)
74. van Haselen RA, Fisher PA. A randomized controlled trial comparing topical piroxicam gel with a homeopathic gel in osteoarthritis of the knee. Rheumatology (Oxford) 2000 Jul; 39 (7): 714-9. (Pubitemid 30487893)
75. Dickson DJ. A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res Clin Exp 1991; 49 (2): 199-207.
76. Bruhlmann P, de Vathaire F, Dreiser RL, et al. Short-term treatment with topical diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomised clinical studies. Curr Med Res Opin 2006 Dec; 22 (12): 2429-38. (Pubitemid 46048358)
77. Peniston JH, Petruschke RA, Gold MS, et al. Safety of topical diclofenac sodium 1% gel: a pooled analysis of randomized controlled trials [abstract]. PainMed 2011; 12 (3): 470-533.
78. Barkin RL. Reducing cardiovascular risks of nonsteroidal anti-inflammatory drugs by using topical formulations [comment]. Am J Cardiol 2009 Nov 1; 104 (9): 1315.
79. Niculescu L, Li C, Huang J, et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. CurrMed Res Opin 2009 Mar; 25 (3): 729-40.
80. RosamondW, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 Feb 6; 115 (5): e69-171.
81. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 Apr; 33 (4): 278-85. (Pubitemid 15087125)
82. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system. Part I: outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005 Jan; 11 (1): 5-15. (Pubitemid 40171222)
83. Malhotra S, Karan RS, Pandhi P, et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001 Nov; 77 (913): 703-7. (Pubitemid 33016070)
84. Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25 (4): 343-55. (Pubitemid 351440452)
85. Shainhouse JZ, Grierson LM, Naseer Z. A long-term, openlabel study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee.AmJ Ther 2010Nov-Dec; 17 (6): 566-76.
86. Peniston JH, Gold MS, Clark MB, et al. An open-label long-term safety trial of diclofenac sodium 1% gel in patients with osteoarthritis of the knee. American Osteopathic Association 2009 Osteopathic Medical Conference & Exposition; 2009 Nov 1-5; New Orleans (LA).
87. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. ArthritisRheum 1994 Jan; 37 (1): 1-9. (Pubitemid 24027687)
88. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenaseindependent actions of cyclooxygenase inhibitors. FASEB J 2001 Oct; 15 (12): 2057-72.
89. Singh P, Roberts MS. Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application. J Pharmacokinet Biopharm 1993 Aug; 21 (4): 337-73. (Pubitemid 24025265)
90. Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996 Sep; 30 (9): 935-40. (Pubitemid 26295242)
91. Algozzine GJ, Stein GH, Doering PL, et al. Trolamine salicylate cream in osteoarthritis of the knee. JAMA 1982 Mar 5; 247 (9): 1311-3. (Pubitemid 12175675)
92. Shackel NA, Day RO, Kellett B, et al. Copper-salicylate gel for pain relief in osteoarthritis: a randomised controlled trial. Med J Aust 1997 Aug 4; 167 (3): 134-6. (Pubitemid 27361724)
93. Chan TY. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol 1996 Sep; 15 (9): 747-50. (Pubitemid 26331690)
94. Chan TY. The risk of severe salicylate poisoning following the ingestion of topical medicaments or aspirin. Postgrad Med J 1996 Feb; 72 (844): 109-12. (Pubitemid 26048231)
95. Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle) 2002 Jun; 14 (2): 188-90. (Pubitemid 34717329)
96. Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. BMJ1979 Mar 10; 1 (6164): 661. (Pubitemid 9145052)
97. Pec J, Strmenova M, Palencarova E, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992 Oct; 50 (4): 307-9.
98. Tanen DA, Danish DC, Reardon JM, et al. Comparison of oral aspirin versus topical applied methyl salicylate for platelet inhibition. Ann Pharmacother 2008 Oct; 42 (10): 1396-401.
99. Heng MC. Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol. Cutis 1987 May; 39 (5): 442-4. (Pubitemid 17099302)
100. Yip AS, Chow WH, Tai YT, et al. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J 1990 May; 66 (775): 367-9. (Pubitemid 20148880)
101. Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Ann Pharmacother 2000 Jun; 34 (6): 729-33. (Pubitemid 30395771)
102. Associated Press. Muscle-pain reliever is blamed for Staten Island runner's death. New York (NY): New York Times, 2007 Jun 10.
103. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview (IL): American Pain Society, 2003.
104. Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999 May; 81 (1-2): 135-45. (Pubitemid 29199909)
105. Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 1998 Nov 1; 18 (21): 8947-59. (Pubitemid 28491759)
106. Altman RD, Aven A, Holmburg CE, et al. Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum 1994; 23: 25-33. (Pubitemid 24209632)
107. Baron R. Capsaicin and nociception: from basic mechanisms to novel drugs. Lancet 2000 Sep 2; 356 (9232): 785-7.
108. Gibbons CH, Wang N, Freeman R. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol 2010 Nov 8; 68 (6): 888-98